NO145657C - Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater. - Google Patents

Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater.

Info

Publication number
NO145657C
NO145657C NO782768A NO782768A NO145657C NO 145657 C NO145657 C NO 145657C NO 782768 A NO782768 A NO 782768A NO 782768 A NO782768 A NO 782768A NO 145657 C NO145657 C NO 145657C
Authority
NO
Norway
Prior art keywords
alkender
derivatives
preparation
physiologically active
analogue procedure
Prior art date
Application number
NO782768A
Other languages
English (en)
Norwegian (no)
Other versions
NO145657B (no
NO782768L (no
Inventor
Dora Nellie Richardson
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of NO782768L publication Critical patent/NO782768L/no
Publication of NO145657B publication Critical patent/NO145657B/no
Publication of NO145657C publication Critical patent/NO145657C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/58—Preparation of carboxylic acid halides
    • C07C51/60—Preparation of carboxylic acid halides by conversion of carboxylic acids or their anhydrides or esters, lactones, salts into halides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO782768A 1977-08-22 1978-08-15 Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater. NO145657C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB3509377 1977-08-22
GB336478 1978-01-27

Publications (3)

Publication Number Publication Date
NO782768L NO782768L (no) 1979-02-23
NO145657B NO145657B (no) 1982-01-25
NO145657C true NO145657C (no) 1982-05-05

Family

ID=26238259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO782768A NO145657C (no) 1977-08-22 1978-08-15 Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater.

Country Status (24)

Country Link
US (1) US4623660A (fr)
EP (1) EP0002097B1 (fr)
JP (1) JPS5444644A (fr)
AR (1) AR218326A1 (fr)
AT (1) AT358023B (fr)
AU (1) AU524339B2 (fr)
BG (1) BG30015A3 (fr)
CA (1) CA1088950A (fr)
CS (1) CS208659B2 (fr)
DD (1) DD138313A5 (fr)
DE (1) DE2860900D1 (fr)
DK (1) DK370778A (fr)
ES (1) ES472742A1 (fr)
FI (1) FI782546A7 (fr)
HU (1) HU177650B (fr)
IE (1) IE47237B1 (fr)
IL (1) IL55387A (fr)
IT (1) IT1098276B (fr)
NO (1) NO145657C (fr)
NZ (1) NZ188151A (fr)
PT (1) PT68458A (fr)
RO (1) RO79083A (fr)
SU (1) SU793382A3 (fr)
YU (1) YU199478A (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3239610A1 (de) * 1982-10-26 1984-04-26 Klinge Pharma GmbH, 8000 München Neue 1,1,2-triphenyl-but-l-en-derivate, sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
CA1289570C (fr) * 1986-06-16 1991-09-24 Tetsuji Asao Derives 1,1,2-triaryl-1-alcenes
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
ATE177008T1 (de) 1992-10-27 1999-03-15 Nippon Kayaku Kk Verwendung von toremifene für die behandlung von sle
US5525633A (en) * 1993-09-24 1996-06-11 Merrell Dow Pharmaceuticals Inc. Triaryl-ethylene derivatives
JPH09503761A (ja) * 1993-09-24 1997-04-15 メレルファーマスーティカルズ インコーポレイテッド 治療に使用するトリアリール−エチレン誘導体類
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
WO1996000090A1 (fr) * 1994-06-27 1996-01-04 Ionix Corporation Analogues d'hormone contenant du bore et procedes d'utilisation de ces derniers pour visualiser ou eliminer des cellules pourvues de recepteurs d'hormones
US5554628A (en) * 1994-09-20 1996-09-10 Eli Lilly And Company Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs
US5658931A (en) * 1994-09-20 1997-08-19 Eli Lilly And Company Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
JPH10509962A (ja) * 1994-11-29 1998-09-29 ヘキスト・マリオン・ルセル・インコーポレイテツド 骨粗鬆症の治療および予防におけるトリアリール−エチレン誘導体の使用方法
US5691384A (en) * 1994-11-29 1997-11-25 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
RU2214236C2 (ru) 1997-08-15 2003-10-20 Дьюк Юниверсити Способ профилактики или лечения эстрогензависимых заболеваний и расстройств
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6395719B1 (en) 1998-06-16 2002-05-28 Eli Lilly And Company Methods for increasing levels of acetylcholine
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US20020147187A1 (en) * 2001-02-22 2002-10-10 Schmidt Jonathan Martin 1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof
AU2003254261B2 (en) * 2002-07-30 2008-04-17 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US7531578B2 (en) * 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
JP2007505881A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−アルキリデン−１９−ノル−ビタミンｄ誘導体およびエストロゲンアゴニスト／アンタゴニストの組合せを含む医薬組成物および方法
WO2005051298A2 (fr) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
CA2549935A1 (fr) * 2003-12-17 2005-07-07 Pfizer Products Inc. Polytherapie continue avec des agonistes selectifs des recepteurs ep4 de la prostaglandine et un oestrogene pour le traitement de pathologies se manifestant par une faible masse osseuse
EP3006039B1 (fr) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides pour stimuler la perte de graisse
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007143607A2 (fr) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Procédé de traitement de la vaginite atrophique
WO2008070496A2 (fr) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company Inhibiteurs d'amino cetp étendus
CL2008002279A1 (es) 2007-08-03 2009-11-27 Summit Corp Plc Combinacion farmaceutica que comprende un compuesto heteroarilbiciclico o arilbiciclico y un agente auxiliar; proceso de preparacion; y envase farmaceutico, util en el tratamiento y/o profilaxis de la distrofia muscular de duchenne, distrofia muscular de becker y caquexia.
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009051908A1 (fr) 2007-10-16 2009-04-23 Repros Therapeutics Inc. Traitement d'un syndrome métabolique par trans-clomiphène
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2819676B1 (fr) 2012-02-29 2018-05-30 Repros Therapeutics Inc. Polythérapie pour le traitement d'une carence en androgène
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9783519B2 (en) * 2015-06-18 2017-10-10 Hong Kong Baptist University Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
WO2019103989A1 (fr) * 2017-11-22 2019-05-31 Temple University-Of The Commonwealth System Of Higher Education Nouveaux éthers de n,n-dialkylamino-phényle fonctionnalisés et leur méthode d'utilisation
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
US20230141863A1 (en) * 2021-11-10 2023-05-11 Northwestern University Small Molecule Inhibitors Targeting the Sodium Channel Tamoxifen Receptor and Uses Thereof
WO2024254189A1 (fr) 2023-06-06 2024-12-12 Daré Bioscience, Inc. Compositions et méthodes de traitement de l'atrophie vulvaire et vaginale (vva)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB879792A (en) * 1956-11-06 1961-10-11 Richardson Merrell Inc Preparation of substituted triphenylethylenes
BE635011A (fr) 1962-07-17
BE637389A (fr) 1962-09-13
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1128379A (en) 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
US3576874A (en) 1967-09-27 1971-04-27 Squibb & Sons Inc 2,2'''-((4,4 - diphenyl-3-buten- and - butylidene) bis (rho-phenyleneoxy))bis triethylamines
US3721712A (en) 1968-08-19 1973-03-20 Richardson Merrell Inc Aminoalkoxy-or aminomethyl-triarylalkenones

Also Published As

Publication number Publication date
ES472742A1 (es) 1979-02-16
IT7826930A0 (it) 1978-08-22
AU524339B2 (en) 1982-09-09
DE2860900D1 (en) 1981-11-05
NO145657B (no) 1982-01-25
YU199478A (en) 1982-10-31
DK370778A (da) 1979-02-23
AU3900678A (en) 1980-02-21
IT1098276B (it) 1985-09-07
IL55387A0 (en) 1978-10-31
SU793382A3 (ru) 1980-12-30
PT68458A (pt) 1978-08-30
IE47237B1 (en) 1984-01-25
NO782768L (no) 1979-02-23
EP0002097A1 (fr) 1979-05-30
BG30015A3 (bg) 1981-03-16
FI782546A7 (fi) 1979-02-23
JPS5444644A (en) 1979-04-09
CS208659B2 (en) 1981-09-15
HU177650B (en) 1981-11-28
NZ188151A (en) 1981-05-29
IL55387A (en) 1982-07-30
EP0002097B1 (fr) 1981-08-05
US4623660A (en) 1986-11-18
RO79083A (fr) 1982-06-25
IE781627L (en) 1979-02-22
ATA610378A (de) 1980-01-15
DD138313A5 (de) 1979-10-24
CA1088950A (fr) 1980-11-04
AT358023B (de) 1980-08-11
AR218326A1 (es) 1980-05-30

Similar Documents

Publication Publication Date Title
NO145657C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater.
NO149035C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive acylanilid-derivater
NO150203C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive 4-hydroksy-2h-1,2-benzotiazin-3-karboksamid-1,1-dioksyder
NO154918C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
NO155774C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazo-diazepin-derivater.
NO782127L (no) Fremgangsmaate for fremstilling av fysiologisk aktive isoksazolo-pyridin-derivater
NO149923C (no) Analogifremgangsmaate for fremstlling av fysiologisk aktive prolinderivater
NO148148C (no) Fremgangsmaate til fremstilling av terapeutisk aktive 4-hydroksy-2-pyrrolidinonderivater
NO156785C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklobutan-derivater.
NO150760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotiazoler.
NO780883L (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive 4-acylamino-fenyl-etanolaminer
NO802015L (no) Fremgangsmaate for fremstilling av fysiologisk aktive indolizin-derivater.
NO147986C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive fenyletylaminer
NO782756L (no) Fremgangsmaate for fremstilling av terapeutisk aktive antrakinonderivater
NO149428C (no) Fremgangsmaate for fremstilling av fysiologisk aktive prostaglandinderivater.
NO149502C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive aminoalkoksyfenylderivater
NO781878L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner.
NO148644C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive sukkerderivater.
NO160370C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive penam-1,1-dioksyd-forbindelser.
NO159090C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.
NO149314C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive imidazoisokinolindioner
NO144928C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive zantinderivater.
NO156167C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolinon-derivater.
NO158800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indenderivater.
NO147483C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive benzylpyrimidiner.